AI, Immunotherapy, and Precision Medicine

Posted on December 30, 2020 by GilPress

Tel-Aviv-based Nucleai is developing AI software for image analysis and modeling of pathology data to assist in the development of more effective drugs.

Read more

About GilPress

I'm Managing Partner at gPress, a marketing, publishing, research and education consultancy. Also a Senior Contributor forbes.com/sites/gilpress/. Previously, I held senior marketing and research management positions at NORC, DEC and EMC. Most recently, I was Senior Director, Thought Leadership Marketing at EMC, where I launched the Big Data conversation with the “How Much Information?” study (2000 with UC Berkeley) and the Digital Universe study (2007 with IDC). Twitter: @GilPress
This entry was posted in AI and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *